Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05180461 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Emodepside Phase II Trial for Treatment of Onchocerciasis

StatusUnknown
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 5, 2024 (before its estimated September 18, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2024); last known: Active, Not Recruiting
  2. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 3
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.
Trial Details
NCT Number NCT05180461
Lead Sponsor Drugs for Neglected Diseases
Collaborators: Bayer
Conditions
(from sponsor)		 Onchocerciasis
Related terms Filariasis, Helminthiasis, Neglected Diseases, Nematode Infections, Onchocerciasis, Onchocerciasis, Ocular, Parasitic Diseases, Skin Diseases, Skin Diseases, Infectious, Skin Diseases, Parasitic
Enrollment 578 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov